Merck KGaA promotes from within new MEA head

pharmafile | October 5, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merck KGaA, biotech, drugs, pharma, pharmaceutical 

Merck KGaA has installed a new head of its healthcare business for the Middle East, Africa and Turkey (MEA) region, by promoting Paolo Carli from within the company. Carli had previously held the position of Managing Director of the Middle East and Egypt region.

Carli had been working in the previous role for 4 and a half years, after having originally joined Merck as a Director of Corporate Finance, a position he worked in for close to five years focusing upon M&A, and was located in Darmstadt, Germany. Prior to this, he had worked at Deutsche Bank as Vice President of Global Business Development.

Commenting on his appointment Paolo Carli said “Merck prepares to celebrate its 350th year in the pharmaceutical business in 2018. Being a strategic region for Merck, we are committed to excel innovation and create value for patients across this region. I am delighted to lead the MEA team. Our innovative treatment options and sustainable commitment for patients will move us to the next level.”

Carli’s new role will see him responsible for leading commercial operations across MEA.

Related Content

Exscientia enters AI drug discovery collaboration with Merck KGaA

Exscientia has announced a new collaboration with Merck KGaA, Darmstadt, Germany, with a focus on …

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Latest content